Swiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.
The European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of €250m.
·
A $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
The only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m.
Danish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
Maastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Newly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.
German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Polish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19